372 related articles for article (PubMed ID: 23644531)
1. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Xu W; Jones M; Liu B; Zhu X; Johnson CB; Edwards AC; Kong L; Jeng EK; Han K; Marcus WD; Rubinstein MP; Rhode PR; Wong HC
Cancer Res; 2013 May; 73(10):3075-86. PubMed ID: 23644531
[TBL] [Abstract][Full Text] [Related]
2. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
5. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
6. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Romee R; Cooley S; Berrien-Elliott MM; Westervelt P; Verneris MR; Wagner JE; Weisdorf DJ; Blazar BR; Ustun C; DeFor TE; Vivek S; Peck L; DiPersio JF; Cashen AF; Kyllo R; Musiek A; Schaffer A; Anadkat MJ; Rosman I; Miller D; Egan JO; Jeng EK; Rock A; Wong HC; Fehniger TA; Miller JS
Blood; 2018 Jun; 131(23):2515-2527. PubMed ID: 29463563
[TBL] [Abstract][Full Text] [Related]
8. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
[TBL] [Abstract][Full Text] [Related]
9. Suppressor of cytokine signaling 1 regulates IL-15 receptor signaling in CD8+CD44high memory T lymphocytes.
Ilangumaran S; Ramanathan S; La Rose J; Poussier P; Rottapel R
J Immunol; 2003 Sep; 171(5):2435-45. PubMed ID: 12928391
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
[TBL] [Abstract][Full Text] [Related]
12. T cell-intrinsic factors contribute to the differential ability of CD8+ T cells to rapidly secrete IFN-γ in the absence of antigen.
Bou Ghanem EN; Nelson CC; D'Orazio SE
J Immunol; 2011 Feb; 186(3):1703-12. PubMed ID: 21191063
[TBL] [Abstract][Full Text] [Related]
13. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
14. AsialoGM1+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-gamma-dependent type 1 immunity.
Kosaka A; Wakita D; Matsubara N; Togashi Y; Nishimura S; Kitamura H; Nishimura T
Int Immunol; 2007 Mar; 19(3):249-56. PubMed ID: 17229818
[TBL] [Abstract][Full Text] [Related]
15. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
[TBL] [Abstract][Full Text] [Related]
17. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8
Wong HC; Jeng EK; Rhode PR
Oncoimmunology; 2013 Nov; 2(11):e26442. PubMed ID: 24404427
[TBL] [Abstract][Full Text] [Related]
18. IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection.
Patil NK; Luan L; Bohannon JK; Guo Y; Hernandez A; Fensterheim B; Sherwood ER
PLoS One; 2016; 11(2):e0148452. PubMed ID: 26859674
[TBL] [Abstract][Full Text] [Related]
19. IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells.
Dhanji S; Teh HS
J Immunol; 2003 Oct; 171(7):3442-50. PubMed ID: 14500639
[TBL] [Abstract][Full Text] [Related]
20. Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors.
Dhanji S; Teh SJ; Oble D; Priatel JJ; Teh HS
Blood; 2004 Oct; 104(7):2116-23. PubMed ID: 15178577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
